Literature DB >> 24716202

Fibroblast growth factor signaling in liver carcinogenesis.

Dalbir S Sandhu, Esha Baichoo, Lewis R Roberts.   

Abstract

Fibroblast growth factors, or FGFs, are a large family of polypeptide cytokines exhibiting a pleiotropy of functions, from cell growth to angiogenesis, wound healing, and tissue repair. This review broadly covers the genetics and protein expression of the FGF family members and the signaling pathways involved in FGF-mediated growth regulation. We emphasize the role of FGFs in the pathogenesis of hepatocellular carcinoma (HCC), including their effects on regulation of the tumor microenvironment and angiogenesis. Finally, we present current views on FGF's potential role as a prognostic marker in clinical practice, as well as its potential as a therapeutic target in HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24716202     DOI: 10.1002/hep.26679

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

1.  An FGFR inhibitor converts the tumor promoting effect of TGF-β by the induction of fibroblast-associated genes of hepatoma cells.

Authors:  H-R Zhang; X-D Wang; X Yang; D Chen; J Hao; R Cao; X-Z Wu
Journal:  Oncogene       Date:  2017-03-06       Impact factor: 9.867

Review 2.  Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Authors:  Kiruthikah Thillai; Paul Ross; Debashis Sarker
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

Review 3.  The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?

Authors:  Sumera Rizvi; Mitesh J Borad
Journal:  J Gastrointest Oncol       Date:  2016-10

Review 4.  Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Authors:  Josep M Llovet; Augusto Villanueva; Anja Lachenmayer; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2015-06-09       Impact factor: 66.675

5.  Emerging roles of FGF signaling in hepatocellular carcinoma.

Authors:  Nana Zheng; Wenyi Wei; Zhiwei Wang
Journal:  Transl Cancer Res       Date:  2016-02       Impact factor: 1.241

Review 6.  FGFs: crucial factors that regulate tumour initiation and progression.

Authors:  Qian Jing; Yuanyuan Wang; Hao Liu; Xiaowei Deng; Lin Jiang; Rui Liu; Haixing Song; Jingyi Li
Journal:  Cell Prolif       Date:  2016-07-07       Impact factor: 6.831

7.  Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.

Authors:  Yu Wang; Xiwei Ding; Shaoqing Wang; Catherine D Moser; Hassan M Shaleh; Essa A Mohamed; Roongruedee Chaiteerakij; Loretta K Allotey; Gang Chen; Katsuyuki Miyabe; Melissa S McNulty; Albert Ndzengue; Emily G Barr Fritcher; Ryan A Knudson; Patricia T Greipp; Karl J Clark; Michael S Torbenson; Benjamin R Kipp; Jie Zhou; Michael T Barrett; Michael P Gustafson; Steven R Alberts; Mitesh J Borad; Lewis R Roberts
Journal:  Cancer Lett       Date:  2016-05-20       Impact factor: 8.679

8.  A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.

Authors:  Sumera Rizvi; Daisaku Yamada; Petra Hirsova; Steven F Bronk; Nathan W Werneburg; Anuradha Krishnan; Warda Salim; Liang Zhang; Eugenia Trushina; Mark J Truty; Gregory J Gores
Journal:  J Biol Chem       Date:  2016-01-29       Impact factor: 5.157

9.  A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma.

Authors:  Chia-Jui Yen; Tae-You Kim; Yin-Hsun Feng; Yee Chao; Deng-Yn Lin; Baek-Yeol Ryoo; Dennis Chin-Lun Huang; David Schnell; Julia Hocke; Arsène-Bienvenu Loembé; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2018-03-15       Impact factor: 11.740

10.  Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.

Authors:  Mahmoud Ma Elsayed; Mahmoud E Mostafa; Eman Alaaeldin; Hatem Aa Sarhan; Montaser ShA Shaykoon; Shady Allam; Ahmed Rh Ahmed; Bakheet Em Elsadek
Journal:  Int J Nanomedicine       Date:  2019-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.